Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with ...

Dec 18 () - Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ​drugs, the company said on Thursday, in a boost to ‌deliver a more ...